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Abstract
Background: Nerve growth factor β (NGFB) is involved in cell proliferation and survival, and it
is a mediator of the immune response. ProNGF, the precursor protein of NGFB, has been shown
to induce cell death via interaction with the p75 neurotrophin receptor. In addition, this
neurotrophin is differentially expressed in males and females. Hence NGFB is a good candidate to
influence the course of multiple sclerosis (MS), much like in the murine model of experimental
autoimmune encephalomyelitis (EAE).
Methods: Ten single nucleotide polymorphisms (SNPs) were genotyped in the NGFB gene in up
to 1120 unrelated MS patients and 869 controls. Expression analyses were performed for selected
MS patients in order to elucidate the possible functional relevance of the SNPs.
Results: Significant association of NGFB variations with MS is evident for two SNPs. NGFB mRNA
seems to be expressed in sex- and disease progression-related manner in peripheral blood
mononuclear cells.
Conclusion:  NGFB variation and expression levels appear as modulating factors in the
development of MS.
Background
Multiple sclerosis (MS) was shown to depend on genetic
components in various twin-, family- and association
based studies[1]. This common neuro-inflammatory dis-
ease with neurodegenerative aspects leads to demyelina-
tion in the central nervous system (CNS)[1]. Complex
interplays of environment and genetic factors are likely
causes for disease development[2]. Yet, it is not entirely
clear why females are usually affected more frequently
than men. In different populations the only virtually con-
sistent MS susceptibility factor is comprised in the HLA-
DRB1  region. Recent studies point to complex allelic
interactions of the HLA-DRB1 locus[3] underscoring pos-
sible (auto-) immune mechanisms in the pathogenesis of
MS. Genetic factors determining susceptibility/disease
progression are only incompletely understood, among
which neurotrophins may be relevant like e.g. ciliary neu-
rotrophic factors.
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Here, we focussed on the nerve growth factor beta (NGFB)
gene known to be involved in many cell regulatory path-
ways including cell survival and proliferation as well as in
immune regulatory processes[4]. Analyses of NGFB in
rodents[5] as well as in humans[6] show sex specific dif-
ferences in secretion levels of the protein, whereby
females have generally lower NGFB protein levels than
males. In addition to crucial involvement in neuro-regula-
tory aspects of NGFB, the gene is located on chromosome
1p13.1, a region reported to be associated with MS, as
revealed by admixture mapping[7]. NGFB has also been
shown to delay the onset of clinical experimental autoim-
mune encephalomyelitis (EAE) as well as to prevent full
development of EAE lesions[8]. Furthermore, anti-NGF
mice reveal a progressive neurodegenerative pheno-
type[9]. Thus, altogether, NGFB is a prominent candidate
gene to influence MS development.
Methods
Samples
DNA samples were genotyped from 1120 unrelated MS
patients (372 males with 31.7 ± 9.8 years at age of onset
and 748 females with 31.5 ± 10.0 years at age of onset),
622 of which showed relapsing remitting (rr), 252 sec-
ondary progressive (sp) and 249 primary progressive (pp)
course according to the Poser criteria as well as 869
healthy blood donors (444 males, 47.9 ± 13.8 years of age
and 425 females, 48.5 ± 16.1 years of age) resided in the
Rhein-Ruhr area (Germany) as detailed in previous stud-
ies[10]. Informed consent has been obtained from all
patients and controls. Research on human DNA for MS
was approved by the ethics commission of the medical
faculty of the Ruhr-University Bochum, Germany.
Genotyping
Genotyping was performed via polymerase chain reaction
(PCR) with subsequent restriction fragment length poly-
morphism (RFLP) analyses or via TaqMan® assays (see
additional file 1, table 3 for detailed information). Statis-
tical analyses were done by χ2 testing with a Bonferroni
corrected statistical significance level. Hardy-Weinberg
equilibrium was evaluated using Pearson's goodness-of-fit
chi-square test (degree of freedom = 1). Power analyses for
this study were performed using GPower software assum-
ing small effect size of 0.20 of the variation, α = 0.05 and
degree of freedom (DF) = 2 (data not shown)[11].
Expression analyses
Fresh peripheral blood mononuclear cells (PBMCs) were
obtained from MS patients in stable phases of the disease.
66% of patients received immunomodulatory treatment
(Copaxone, MX, Betaferon and Cortison). RNA of 23
male patients (of which eight suffered from rr (three Ø
treatment), eleven from sp (three Ø treatment) and four
from pp MS (one Ø treatment)) as well as ten females (of
which five showed rr (two Ø treatment) and five sp (two
Ø treatment) MS course) was isolated using the RNeasy
kit (Qiagen). Expression analyses were performed using
QuantiTect® SYBR® Green one-step RT-PCR (Qiagen). The
quantification of NGFB RNA was analysed using the ΔΔCt
method. Oligonucleotides used were F-GCT TTC TAT CCT
GGC CAC A, R-CAG GGA CAT TGC TCT CTG AG for the
analysed NGFB as well as F-AGG TCG GAG TCA ACG GAT
TTG, R-AAG CAG CCC TGG TGA CCA G for GAPDH as
reference system. Statistical analyses were performed
using t-tests (statistical program for the social sciences;
SPSS).
Results
We report genotyping data of ten SNPs covering the cod-
ing region of the NGFB gene with subsequent expression
analysis in 23 male and ten female MS patients. A map of
the genotyped SNPs in the NGFB gene is depicted in figure
1. Initial genotyping was performed for rs6330 located in
exon 3 of the NGFB gene, since this exon encodes the pre-
cursor protein proNGF exclusively. rs6330 showed signif-
icant association in allele (p = 0.0038; OR = 1.210
(1.063–1.377)) and genotype frequencies (p = 0.0126)
when comparing healthy controls and MS patients. Inter-
estingly, the strongest association was observed mainly for
male rr MS patients for allele (p = 0.0087; OR = 1.386
(1.086–1.770)) and genotype frequencies (p = 0.0230)
when stratifying the cohorts by sex and disease progres-
sion, although the C allele was in general increased in all
Schematic representation of the NGFB gene structure and the location of the genotyped SNPs Figure 1
Schematic representation of the NGFB gene structure and the location of the genotyped SNPs.
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Table 1: Detailed analysis for rs6330, genotyped in 1120 and 869 controls.
Genotype (%) p value
SNP
(maj./min. 
allele)
cohort Stratif-
ication
Maj. allele 
(%)
Min. allele 
(%)
p value OR (CI*1)X X X x x x G e n o -
type
Major allel 
dominant
co-
dominant
Minor 
allele 
dominant
HWE p 
value
N
rs6330 
(C/T)
MS Ø 1235 
(57.2)
923 
(42.8)
0.0038 1.210
(1.063–
1.377)
356 
(33.0)
523 
(48.5)
200 
(18.5)
0.0126 0.0579 0.3034 0.0056 0.75 1079
male 438 
(59.8)
294 
(40.2)
0.0087 1.308
(1.070–
1.599)
133 
(36.3)
172 
(47.0)
61 (16.7) 0.0247 0.1109 0.2403 0.0091 0.67 366
female 797 
(55.9)
629 
(44.1)
0.0598 1.149
(0.946–
1.395)
223 
(31.3)
351 
(49.2)
139 
(19.5)
0.1672 0.1665 0.6840 0.0938 0.97 713
rr Ø 677 
(56.9)
513 
(43.1)
0.0211 1.193
(1.015–
1.210)
192 
(32.3)
293 
(49.2)
110 
(18.5)
0.0647 0.1011 0.5493 0.0345 0.92 595
rr male 240 
(61.2)
152 
(38.8)
0.0087 1.386
(1.086–
1.770)
75 (38.3) 90 (45.9) 31 (15.8) 0.0230 0.1196 0.2226 0.0081 0.65 196
rr female 437 
(54.8)
361 
(45.2)
0.2276 1.098
(0.885–
1.361)
117 
(29.3)
203 
(50.9)
79 (19.8) 0.4648 0.2701 0.9151 0.3737 0.59 399
sp Ø 271 
(56.5)
209 
(43.5)
0.1276 1.173
(0.955–
1.439)
78 (32.5) 115 
(47.9)
47 (19.6) 0.2503 0.4119 0.4231 0.1016 0.69 240
sp male 73 (55.3) 59 (44.7) 0.6597 1.086
(0.752–
1.569)
21 (31.8) 31 (47.0) 14 (21.2) 0.7583 0.9914 0.5229 0.4839 0.69 66
sp female 198 
(56.9)
150 
(43.1)
0.1082 1.197
(0.915–
1.565)
57 (32.8) 84 (48.3) 33 (19.0) 0.2593 0.2818 0.6243 0.1264 0.84 174
pp Ø 287 
(58.8)
201 
(41.2)
0.0143 1.291
(1.052–
1.584)
86 (35.2) 115 
(47.1)
43 (17.6) 0.0369 0.1358 0.3070 0.0137 0.67 244
pp male 125 
(60.1)
83 (39.9) 0.0759 1.322
(0.971–
1.800)
37 (35.6) 51 (49.0) 16 (15.4) 0.1967 0.1883 0.6930 0.1116 0.82 104
pp female 162 
(57.9)
118 
(42.1)
0.0779 1.245
(0.933–
1.660)
49 (35.0) 64 (45.7) 27 (19.3) 0.1540 0.3615 0.3297 0.0557 0.46 140
control Ø 857 
(52.5)
775 
(47.5)
221 
(27.1)
415 
(50.9)
180 
(22.1)
0.57 816
male 443 
(53.2)
389 
(46.8)
115 
(27.6)
213 
(51.2)
88 (21.2) 0.56 416
female 414 
(51.7)
386 
(48.3)
106 
(26.5)
202 
(50.5)
92 (23.0) 0.82 400
Significance threshold: p = 0.025 (Bonferroni corrected for 2 SNPs). Significant values indicated by bold letter;
1CI = 95%. HWE: Hardy-Weinberg equilibrium, Pearson's goodness-of-fit chi-square (degree of freedom = 1).BMC Medical Genetics 2008, 9:107 http://www.biomedcentral.com/1471-2350/9/107
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MS sub-cohorts (see table 1). Subsequent genotyping of
three flanking SNPs (rs6327, rs7523831 and rs11102915)
in subgroups of our cohorts of 263 rr MS patients and 259
controls showed no additional significant association (see
additional file 1, table 4), thus restricting the region of
interest. Further SNP genotyping in the vicinity of exons 1
and 2 was performed in order to clarify putative impor-
tance of these non-protein coding regions. No significant
association was found for SNPs rs2239622 and rs910330
flanking exon 2 in the subgroups of our cohorts (see addi-
tional file 1, table 4).
A tendency for MS association of the promoter SNP
rs11102930 was observed for the co-dominant transmis-
sion model for the subgroup of 263 rr MS patients as com-
pared to healthy controls (see additional file 1, table 4).
Gender stratification showed, despite of decreased power,
significant association of rs11102930 in male MS patients
compared to male controls for the co-dominant transmis-
sion model (data not shown). Female MS patients did not
show conspicuous differences when compared to healthy
female controls. Analyses of three flanking SNPs,
rs3811014, rs17540656 and rs6673867 in the defined
subgroups showed no significant association for male MS
patients compared to healthy male controls as well as no
significant association between female MS patients and
female controls, respectively (data not shown). The con-
spicuous tendency of sex-specific association of
rs11102930 SNP in male MS patients was confirmed
when additionally the remaining individuals were geno-
typed (860 unrelated MS patients and 611 controls, p =
0.0115; OR = 0.765 (0.622–0.942)). Further stratification
of all tested MS patients for disease progression indicates
despite the small male rr MS cohort size (n = 179) that the
significant association is eventually based on the differ-
ence in allele (p = 0.0101; OR = 0.717 (0.557–0.924))
and genotype (p = 0.0206) frequency distributions of
male rr MS patients compared to healthy male controls
(see table 2).
23 male MS patients were characterized via quantitative
RT-PCR after selection for opposite homozygosity in
rs11102930: No correlation was observed between geno-
types and expression levels. Yet, correlating with disease
progression reveals significant differences in NGFB RNA
expression levels between rr and sp/pp MS patients,
respectively (p = 0.003; see figure 2). We evaluated the
NGFB expression levels in correlation with disease course
also in females, although no differences were observed in
the allele and genotype frequencies for rs11102930. Five
female patients with rr MS were compared to five female
patients with sp course, both harboring the more frequent
homozygous genotype for rs11102930. The two groups
showed no tendencies for different expression profiles.
Influence of MS treatment on the observed expression
data was not evident.
Discussion
NGFB as well as its precursor protein proNGF have been
shown to be involved in several crucial processes relating
to MS pathogenesis. NGFB itself, in addition to its impor-
tant role as modulatory mediator of the immune
response[12], initiates and maintains cell proliferation
and survival. In contrast, proNGF has been shown to
induce cell death via interaction with the p75 neuro-
trophin receptor[13]. Here we present genotyping data of
the NGFB gene for ten selected SNPs in up to 1120 unre-
lated MS patients and 869 controls. Of ten tested SNPs
two show significant association in sex- and disease pro-
gression-specific manner, whereby rs6330 is located in
exon 3 and rs11102930 in the promoter region of the
NGFB gene (see figure 1). SNP rs6330 is defined as a C/T
exchange leading to the non-synonymous amino acid
substitution of alanine to valine in position 35. The
increase in amino acid size could modify the tertiary struc-
ture of proNGF, leading to altered interaction and signal-
ling via the p75 neurotrophin receptor. Since the C allele
is more frequent in MS patients compared to healthy con-
trols (57.2% vs. 52.5%), this allele could represent a risk
factor due to its possible role in inducing increased cell
death via enhanced interaction with the p75 neuro-
trophin receptor. Interestingly, male MS patients seem to
have a higher risk than female MS patients (see table 1).
The actual effect of the amino acid exchange on eventually
altered interaction of proNGF and the p75 neurotrophin
receptor has to be shown definitively in follow-up studies
in order to clarify any functional relevance.
rs11102930 is located in the promoter region of the NGFB
gene and has been shown via electrophoretic mobility
shift assays to be functionally relevant by affecting the
binding of the vitamin D receptor (VDR) to its DNA
motif[14]. VDR has a higher binding affinity for the C
than for the T allele. Interestingly, VDR variation itself has
been found to be associated with MS [15] and it affects the
EAE course in the mouse model[16]. For our MS cohort,
we show that only male patients have a significantly
increased frequency of the C allele punc = 0.01 and a signif-
icant effect in the C dominant model for the genotype dis-
tribution punc = 0.0075 (see table 2). Further stratification
of male MS patients for rs11102930 association indicates
that only male rr MS patients show a significantly
increased frequency of the C allele punc = 0.01. This effect
has to be verified in larger male (rr) MS cohorts in order
to provide convincing statistical power. Under the
assumption of enhanced NGFB expression due to the
higher affinity of the VDR binding in case of the C allele,
we propose a protective effect of the C allele due to higher
NGFB levels and its cell proliferating and survival mediat-B
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Table 2: Detailed analysis for rs11102930, genotyped in 1120 and 869 controls.
Genotype (%) p value
SNP
(maj./min. 
allele)
cohort Stratif-
ication
Maj. allele 
(%)
Min. allele 
(%)
p value OR (CI*1)X X X x x x G e n o -
type
Major allel 
dominant
co-
dominant
Minor 
allele 
dominant
HWE p 
value
N
rs1110293
0 (T/C)
MS Ø 1380 
(64.3)
766 
(35.7)
0.5414 0.959 
(0.840–
1.096)
449 
(41.8)
482 
(44.9)
142 
(13.2)
0.6694 0.3713 0.7157 0.8148 0.48 1073
male 423 
(60.8)
273 
(39.2)
0.0115 0.765 
(0.622–
0.942)
124 
(35.6)
175 
(50.3)
49 (14.1) 0.0259 0.2272 0.0664 0.0075 0.31 348
female 957 
(66.0)
493 
(34.0)
0.2271 1.115 
(0.934–
1.332)
325 
(44.8)
307 
(42.3)
93 (12.8) 0.1682 0.8954 0.0695 0.0829 0.13 725
rr Ø 764 
(65.1)
410 
(34.9)
0.9120 0.991 
(0.848–
1.158)
251 
(42.8)
262 
(44.6)
74 (12.6) 0.8773 0.6845 0.7010 0.9061 0.66 587
rr male 212 
(59.2)
146 
(40.8)
0.0101 0.717 
(0.557–
0.924)
59 (33.0) 94 (52.5) 26 (14.5) 0.0206 0.2537 0.0465 0.0056 0.24 179
rr female 552 
(67.6)
264 
(32.4)
0.0760 1.201 
(0.981–
1.472)
192 
(47.1)
168 
(41.2)
48 (11.8) 0.0872 0.7263 0.0525 0.0295 0.23 408
sp Ø 303 
(62.9)
179 
(37.1)
0.3324 0.901 
(0.731–
1.112)
97 (40.2) 109 
(45.2)
35 (14.5) 0.5288 0.2712 0.8855 0.5545 0.63 241
sp male 78 (59.1) 54 (40.9) 0.0764 0.714 
(0.491–
1.036)
23 (34.8) 32 (48.5) 11 (16.7) 0.2125 0.2026 0.4665 0.1183 0.98 66
sp female 225 
(64.3)
125 
(35.7)
0.7989 1.034 
(0.798–
1.341)
74 (42.3) 77 (44.0) 24 (13.7) 0.6875 0.7015 0.3886 0.5387 0.58 175
pp Ø 313 
(63.9)
177 
(36.1)
0.5743 0.942 
(0.764–
1.161)
101 
(41.2)
111 
(45.3)
33 (13.5) 0.7926 0.5014 0.9019 0.7477 0.77 245
pp male 133 
(64.6)
73 (35.4) 0.5167 0.900 
(0.655–
1.237)
42 (40.8) 49 (47.6) 12 (11.7) 0.7250 0.8995 0.4775 0.4289 0.69 103
pp female 180 
(63.4)
104 
(36.6)
0.9694 0.995 
(0.753–
1.314)
59 (41.5) 62 (43.7) 21 (14.8) 0.6352 0.4961 0.3850 0.6777 0.48 142
control Ø 1121 
(65.3)
597 
(34.7)
364 
(42.4)
393 
(45.8)
102 
(11.9)
0.79 859
male 585 
(66.9)
289 
(33.1)
197 
(45.1)
191 
(43.7)
49 (11.2) 0.79 437
female 536 
(63.5)
308 
(36.5)
167 
(39.6)
202 
(47.9)
53 (12.6) 0.50 422
Significance threshold: p = 0.025 (Bonferroni corrected for 2 SNPs). Significant values indicated by bold letter;
1CI = 95%. HWE: Hardy-Weinberg equilibrium, Pearson's goodness-of-fit chi-square (degree of freedom = 1).BMC Medical Genetics 2008, 9:107 http://www.biomedcentral.com/1471-2350/9/107
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NGFB expression profile comparison of male rr vs. sp/pp MS patients and female rr vs. sp MS patients, respectively Figure 2
NGFB expression profile comparison of male rr vs. sp/pp MS patients and female rr vs. sp MS patients, respec-
tively. Significant differences are obvious between male MS patients with different course of the disease; *p = 0.003 (SPS t-
test).
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ing properties, thus preventing chronic disease progres-
sion. Although rs11102930 is reported to alter the
binding affinity of the VDR, the expression regulatory
influence has still to be shown via in vitro reporter assays.
Our analyses of the rs11102930 genotype on the expres-
sion profile revealed no correlation of the genotype pat-
terns for SNP rs11102930 and NGFB levels. Yet, male rr
MS patients have a 2.5 fold elevated expression in com-
parison to male sp + pp MS patients as shown in figure 2
(or only male sp MS, data not shown). Both, sp and pp MS
patients were evaluated in combination because of
chronic disease progression. This expression difference
based on disease progression differentiation was not
observed in female MS patients perhaps due to the small
sample size, differences in menstruation cycle stages (no
information available) or perhaps there are no differ-
ences. Comparison between female and male MS patients
were not feasible since sex-specific expression differences
have been described for healthy controls[5,6].
Our results indicate a disease modulating role of NGFB for
MS progression as shown in the EAE model[8]. The previ-
ously reported lower NGFB levels in healthy females com-
pared to healthy males could perhaps partially explain
why females are affected twice as often as males with MS
based on the neuro-protective and cell proliferative stim-
ulating properties of NGFB. Since the serum level of NGFB
is low in females and, in addition, depends on the men-
strual cycle phase[17], marginal modulations of NGFB
expression or NGFB interactions may have no profound
effects on disease progression in women. This fact could
explain why no significant differences in genotype and
allele frequency patterns for rs6330 and rs11102930 were
observed in the analysed female MS patients. Under this
assumption we hypothesise in the case of rs6330, the C
allele to be a risk factor for MS by eventually modulating
the interaction of the proNGF with the p75 neurotrophin
receptor and thus promoting cell death. In contrast the
rs11102930 C allele located in the promoter region might
provide protection for male MS patients, eventually pre-
venting chronic disease progression due to perhaps
increased NGFB expression. Which of the significantly
associated SNPs are responsible for the change in expres-
sion profile of NGFB? No correlation could be drawn
between the expression results and the genotype pattern.
Hence, it is likely that combined effects of the tested SNPs
lead to the observed results. According to our expression
lower NGFB concentration in male MS patients may lead
to chronic disease progression (see figure 2). Such an
assertion needs to be verified independently.
The complex LD patterns for the 52.32 kilobase pair long
sequence (see HapMap data) and the haplotype analysis
for the 10 tested SNPs make predictions of putative inter-
actions of rs6330 with rs11102930 largely impossible (see
additional file 1, figure 3 for detailed information). Con-
versely, it is theoretically possible that other linked
sequence variations are responsible for the observed phe-
nomena.
Conclusion
NGFB as multifunctional protein might affect MS courses
differentially as well as other neurodegenerative diseases
in a complex manner. Therefore, further detailed studies
appear warranted.
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